Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Artificial Tears for the Reduction of Radioiodine Levels in the Nasolacrimal Duct System of Patients with Thyroid Carcinoma following Radioiodine Therapy

This phase II trial studies how well artificial tears works in reducing radioiodine levels in the nasolacrimal duct system in patients with thyroid carcinoma following radioiodine therapy. Radioactive iodine therapy for thyroid carcinoma has been associated with nasolacrimal duct obstruction. Artificial tears may dilute the amount of radioactive iodine in the tears of the eyes, thus decreasing uptake by the cells lining the nasolacrimal duct system.
Thyroid
Phase II
Both
Not Available
Not Available
Sobel, Rachel
Local
Vanderbilt University
09-21-2020
Prevention
VICCHN2018
NCT04327999

Eligibility

0 Years
BOTH
NO
Inclusion Criteria:

Radio-iodine therapy for thyroid cancer

Radioiodine therapy >= 150 mCi

Patient wears contacts on both eyes



Exclusion Criteria:

Use of eye drops, other than artificial tears

History of ocular/lacrimal gland trauma

History of lacrimal drainage disease: canaliculitis, dacryocystitis

Prior radiotherapy

Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)

Medical conditions that predispose to nasolacrimal duct (NLD) stenosis * Sarcoid * Granulomatosis with polyangiitis * Chronic lymphocytic leukemia

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: